NCT00644007

Phase III Study to Assess the Efficacy and Safety of SK3530 in Patients With Erectile Dysfunction and Hypertension

A Double Blind, Randomized, Placebo-controlled, Parallel Group, Multi-center, Phase III Study to Assess the Efficacy and Safety of SK3530 in Patients With Erectile Dysfunction Taking Antihypertensive Medication

• Status: Completed
• Phase: Phase 3
• Study type: Interventional
• Enrollment: 109 (actual)
• Sponsor: SK Chemicals Co., Ltd. · Industry
• Sex: Male
• Age: 19 Years
• Healthy volunteers: Not accepted

Summary

The purpose of this study is to evaluate the efficacy and safety of SK3530 in men with ED and hypertension who were taking antihypertensive medication.

Detailed description

SK3530 is a potent and selective phosphdiesterase type 5(PDE 5) inhibitor developed for the treatment of erectile dysfunction(ED). Since ED is common in men with hypertension, it is important to determine the efficacy and safety of SK3530 in men with ED taking antihypertensive medication.

Conditions

• Erectile Dysfunction

Interventions

Type	Name	Description
DRUG	Placebo	Placebo as a substitute of SK3530 100mg
DRUG	SK3530	SK3530 100 mg

Timeline

• Start date: 2007-12-01
• Primary completion: 2008-09-01
• Completion: 2008-12-01
• First posted: 2008-03-26
• Last updated: 2013-04-18

Locations

1 site across 1 country: South Korea